Tango Therapeutics Inc (TNGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.32B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tango Therapeutics Inc (TNGX) Competitors
The companies most similar to Tango Therapeutics are Telix Pharmaceuticals (TLX), Legend Biotech (LEGN) and Tarsus Pharmaceuticals (TARS). By market cap, Tango Therapeutics ranks 7th of the 13 companies on this page; TG Therapeutics (TGTX) is the largest at $9.75B. The median P/E of the 3 companies with a P/E is 87.2x.
Peer Comparison
TNGX's revenue growth of -100.0% is below the peer median of 27.1%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) | $4.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $3.14B | N/A | 5.3x | 3.8% | -0.7% | 22.3% | 0.00% |
| Legend Biotech Corp (LEGN) | $3.39B | 266.5x | 2.3x | -0.0% | N/A | 32.0% | 0.00% |
| Tarsus Pharmaceuticals Inc (TARS) | $3.96B | N/A | 5.4x | -102.9% | -393.6% | 63.9% | 0.00% |
| Enliven Therapeutics Inc. (ELVN) | $3.59B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Protagonist Therapeutics Inc (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Erasca Inc (ERAS) | $5.50B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Viridian Therapeutics Inc (VRDN) | $3.51B | N/A | 128.5x | 0.0% | -41.8% | -63.5% | 0.00% |
| PTC Therapeutics Inc (PTCT) | $5.30B | N/A | 5.2x | -9.2% | 18.1% | 69.6% | 0.00% |
| Peer median | $4.56B | 87.2x | 8.2x | 0.0% | -21.1% | 27.1% | 0.00% |
Similar Companies
These are the 12 companies most similar to Tango Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Telix Pharmaceuticals Limited (TLX) | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic... | |
| Legend Biotech Corp (LEGN) | Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology... | LEGN competitors |
| Tarsus Pharmaceuticals Inc (TARS) | Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates... | TARS competitors |
| Enliven Therapeutics Inc. (ELVN) | Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare... | ELVN competitors |
| CG Oncology, Inc. Common stock (CGON) | CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070... | CGON competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Protagonist Therapeutics Inc (PTGX) | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical... | PTGX competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Erasca Inc (ERAS) | Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers... | ERAS competitors |
| Viridian Therapeutics Inc (VRDN) | Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. | VRDN competitors |
| PTC Therapeutics Inc (PTCT) | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. | PTCT competitors |
Frequently Asked Questions About TNGX
Who are Tango Therapeutics' main competitors?
The companies most similar to Tango Therapeutics include Telix Pharmaceuticals (TLX), Legend Biotech (LEGN), Tarsus Pharmaceuticals (TARS), Enliven Therapeutics (ELVN) and CG Oncology, Inc. Common stock (CGON), listed from the closest match.
Who is Tango Therapeutics' biggest competitor?
TG Therapeutics (TGTX) is the largest of the similar companies at $9.75B; Telix Pharmaceuticals (TLX) is the closest match by business profile, size, sector and industry.
How does TNGX stock compare with its competitors?
TNGX's net margin is 0.0% against a peer median of 0.0%.
Which of Tango Therapeutics' competitors pays a higher dividend?
Tango Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Tango Therapeutics bigger than its competitors?
No. Tango Therapeutics is 7th by market cap among the 13 companies on this page; the largest is TG Therapeutics (TGTX) at $9.75B.
TNGX pages: Overview, Earnings, Forecast, Financials, Competitors